Australian Prescriber

12/06/2025

👏Congratulations to Dr Michael Steiner, Australian Prescriber’s stakeholder network representative for the Royal Australian and New Zealand College of Ophthalmologists, who has been recognised in the 2025 King’s Birthday Honours!

🏆Dr Steiner was awarded Member of the Order of Australia (AM) for his significant service to medicine in ophthalmology as a surgeon and to professional associations.

📣We’re proud to celebrate his achievement and thank him for his dedication and valuable contributions to the field of ophthalmology and to Australian Prescriber.

12/06/2025

Did you know pharmacogenomic tests provide information on gene variants that may influence drug exposure or response? They can be used to help tailor drug therapy to a patient, for example, by identifying whether they are at higher risk of a serious adverse drug reaction or treatment failure. Read more: https://bit.ly/45C9idV

11/06/2025

What factors influence optimal choice of contraception? This article provides an update on both long- and short-acting contraceptive methods. It discusses factors influencing choice of contraception, including key considerations for different population groups, such as people who are postpartum, and young people.
Learn more: https://bit.ly/43J9l51

09/06/2025

The June Issue of is out👉: https://bit.ly/3SzpB3J. The new issue features an update on long- and short-acting contraceptive methods, to personalise drug therapy, the latest management approaches for , medicines for treating opioid dependence, and more!

26/05/2025

How does noninvasive prenatal testing (NIPT) differ from other screening options like serum screening and ultrasound? Genetic counsellor Alice Poulton joins Justin Coleman to explain how NIPT is used to screen for conditions such as Down syndrome, how to interpret results, and when invasive testing may be considered.
🎧Listen here: https://bit.ly/43s7D8b

24/05/2025

A new drug has been approved in Australia for disease (the first in 20+ years). So, where will this potentially disease-modifying drug (donanemab; trade name Kisunla) fit into the management of dementia? Who will benefit and what are the risks? Read this article https://bit.ly/4kqTnU6 or listen to this podcast https://bit.ly/4dwe7HB with geriatrician A/Prof Louise Waite for a quick overview of new treatments for Alzheimer disease.

12/05/2025

📢What’s new in prevention and management? In this latest episode, David Liew chats with infectious diseases physician Linny Phuong about updated prevention and management strategies for RSV, including when to test, who’s most at risk, and what immunisation options are available.
Listen now: https://bit.ly/3GGA1M9

05/05/2025

🎙️ New ! So, what has changed in the latest version of Therapeutic Guidelines: Antibiotic? Dhineli Perera chats with Allen Cheng, director of Infectious Diseases at Monash Health and member of the Antibiotic Expert Group.
Topics include:
✅ A new tiered approach to sepsis management
✅ Changes to severity assessment and treatment for community-acquired pneumonia
✅ Revised antimicrobial dosing advice
...and more👉 https://bit.ly/3YOGdrN

05/05/2025

🤔 🗯️ Did you know clonazepam oral liquid should be ordered and measured in DROPS💧, not millilitres? Standardising the way this medicine is ordered and measured can reduce the risk of errors like the one described in this article.
👉 https://bit.ly/3GtM5jA

Australian Prescriber is a free, independent peer-reviewed journal that healthcare professionals have trusted for half a century! Since 1975, the journal has evolved and grown, and this year we celebrate its 50-year anniversary.

29/04/2025

This article discusses key principles for optimising the safe and effective use of . Learn why therapeutic drug monitoring based on the area under the concentration–time curve (AUC) is recommended over trough concentrations in many patients, and some considerations for implementing this approach in clinical practice.
Read more: https://bit.ly/3ECtMbw

28/04/2025

Noninvasive prenatal testing ( ) is one of 3 options to screen for fetal chromosome conditions such as Down syndrome. NIPT has a high level of accuracy. Genetic counselling and confirmatory invasive testing are recommended for patients with a high-probability result. Learn more about NIPT: https://bit.ly/4lJyWmM

23/04/2025

Have you heard about calcitonin gene-related peptide (CGRP)–targeted therapies and their role in management? monoclonal antibodies are available as self-administered subcutaneous injections or as an intravenous infusion and are given monthly or every 3 months. Small-molecule CGRP receptor antagonists, also known as ‘gepants’, are oral medications that can be used to prevent or treat migraine attacks. Read more: https://bit.ly/444KASU